Scientists Have Discovered A New Method Of Detecting Cancer

Scientists Have Discovered A New Method Of Detecting Cancer.
A unexplored study marketed as an alternative to a mammogram for breast cancer detection is not an impressive screening TOOL, US health officials say. With the nipple aspirate test, a bust pump collects fluid from a woman's nipple. The fluid is then examined for eccentric and potentially cancerous cells. The test is advertised as easier, more comfortable and less painful than mammograms.

However, there is no ammunition to support claims that the test can detect breast cancer, said Dr David Lerner, a medical official at the US Food and Drug Administration and a breast imaging specialist. "FDA's trouble is that the nipple aspirate test is being touted as a standalone tool to screen for and distinguish breast cancer as an alternative to mammography," Lerner said in an agency news release.

So "Our horror is that women will forgo a mammogram and have this test instead". Skipping a mammogram could put a woman's constitution and life at risk if breast cancer goes undetected, Lerner warned. He said there is no detailed evidence that the nipple aspirate test, when used on its own, is an effective screening tool for knocker cancer or any other medical condition.

The test is still being studied to determine if it might be useful in combination with other methods to cover for disease. "The bottom line is that women should not rely solely on these nipple aspirate tests for the screening or diagnosis of chest cancer. Mammography is still the gold standard".

In October, 2013, Atossa Genetics pulled its nipple aspirate exam - called the ForeCYTE Breast Health Test - off the shop after being warned by the FDA that its claims about the test were unsubstantiated. The company claimed the assess was "literally a Pap smear for breast cancer". Pap smears are a standard evaluate for cervical cancer.

And Women who have had a nipple aspirate test as a form of breast cancer screening should also have a mammogram, according to screening guidelines or as recommended by their doctor. Also, they should minimize to their doctor about whether additional tests are needed, the FDA said. One in eight US women will strengthen breast cancer in her lifetime continue. The affliction is the second leading cancer killer of women in the country.